Epillo Health Systems got evaluated at a whopping figure of USD 150 MN for their innovative digital health technology
The enthralling research report by Sagacious IP exploring
growth probabilities for a Decentralized Med-Tech company working in the domain
of Digital Healthcare Management is an interesting read for businesses in Medicine
management and healthcare enthusiasts.
A Hybrid Approach was followed by Sagacious IP (a Multi-National valuation firm with offices located in USA,
Japan, China, Canada, India and Netherlands) to evaluate an appropriate fair
market value for the Innovative Digital Health Technology name Epillo Health
Systems under a study. This involved market analysis of the technology under
study, revenue generated by the implementation of subject technology, freshness
and disruptive nature of the technology, market size, potential user-base
(People on Prescription plans), discount rate, etc. Along with these, many
other factors influencing the market were considered to arrive at a Net Fair
Market value of USD 149.15 Million within six months of its operations.
Addressing the growing global concern towards Precision and
Effective medicine, Adverse Drug Events (ADEs), Unsupervised Drug-Food and
Drug-Drug Interactions, Drug Adherence, Food safety and traceability, and
Healthcare Data secure storage, management, transmission and privacy concerns,
Epillo’s proprietary Intellectual Property (IP): Blockchain based Digital
Therapeutic Devices to predict Drug-Food constituent Interactions are uniquely
capable of managing, tracking, and detecting Drug-Food Interactions in real
time, provide deep insights into the lifestyle of Patients and assist the
co-administration of Drug Plans
(Therapeutic Prescription Drugs) and Food Products in real time, thereby
improving the quality of life of Millions of people around the world, by
tackling Drug-Food and Drug-Drug Interactions in real time.
Aasif Shah, CEO at Epillo Health Systems, said: “We are
excited about the evaluation of our technology as this gives us more confidence
to be launching our product in the global market. We want to reach out to more
and more people and want them to be benefitted out of this platform. With our
technology INTRx, we can help combat millions of unsupervised Drug-Food and
Drug-Drug Interactions can positively impact lifestyle and efficiency of
medicines and treatment plans for millions around the world, while also
providing new output data points to clinicians to understand their patients
better and imbibe more care into the healthcare system’’.
This invention provides a new and useful
method for patient engagement in the field of Digital Therapeutic Devices (or,
Software-based Therapeutics) used in conjunction with traditional drug plans to
optimize patient care, smart engagement and tracking clinical outcomes. The
present invention provides systems and methods powered by a set of algorithm
and machine learning models with the security, safety, consent sharing, and smart
contract features of a blockchain distributed ledger model to create a patient
facing system and clinical tools.
“Our Recent technological
advancements make it possible to monitor individuals closely and continuously
on multiple scales in real time while incorporating genetic, environmental, and
lifestyle information. We are collecting and using this multi-scale biomedical
data to gain a more precise understanding of health, disease, and lifestyle at
molecular and physiological levels and developing actionable, predictive health
models for preventing Drug-Food and Drug-Drug Interactions based on
immutable decentralized models for a safer world.” Says Dr. Bhupinder Singh (CoB – Epillo Health
Systems). This assessment by Sagacious IP validates our approach and ability to
bring a revolution in the field of healthcare management by integrating AI
(artificial Intelligence) along with decentralized Med-Tech to achieve our goal
to provide healthier and safer lifestyle choice to the people.
About Epillo
Epillo Health Systems is a digital healthcare
company based out of Estonia with aimed at transforming the medical technology
landscape by incorporating the best of artificial intelligence, machine
learning and blockchain in digital healthcare through their proprietary Medical and Pharmacological AI based
application named ‘’INTRx’’. They are developing technology
solutions and deep insights to enable care teams to deliver better, faster and
more connected care. Epillo having its Patent-pending innovations in 153
countries through the United States Patent & Trademark Office (USPTO) and
27 countries of the European Union (EU) through the European Patent Office
(EPO), is working to transform the Digital Healthcare technology landscape by
incorporating the best of Artificial Intelligence, Machine learning, and
Blockchain in Digital Healthcare. To know more regarding their product and
vision, visit: https://www.epillo.com/
Comments
Post a Comment